AzTrials
AzTrials

Depressive Disorder, MajorPhase 3NCT02709655

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 98 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years). Read more about this study

Who is it for?
Ages 7 to 11 years
Conditions the study is for
Depressive Disorder, Major
What is being tested?
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
683 participants
Where
98 sitesin 19 countries
Study dates
18 May 2016to 21 Jan 2022
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • The participant has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™).
  • The participant has a CDRS-R total score ≥45 at the Screening Visit and the Baseline.
  • The participant has a CGI-S score ≥4 at the Screening Visit and the Baseline.
  • The participant is a boy or girl, aged ≥7 and <12 years at Screening Visit
  • The participant has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.

Who cannot join

  • The participant has participated in a clinical study <30 days prior to the Screening Visit.
  • The participant has previously participated in a study with vortioxetine.
  • Other protocol defined inclusion and exclusion criteria may apply

Trial locations and contacts

98 sites in 19 countries.

98 sites in 19 countries

United States34 sites
  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331

  • BioBehavioral Research of Austin

    Austin, Texas, 78759

  • Kennedy Krieger Institute

    Baltimore, Maryland, 21205

  • American Medical Research, Inc.

    Chicago, Illinois, 60612

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219

  • University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry

    Cleveland, Ohio, 44012

  • Westside Medical

    Clinton, Utah, 84015

  • Sarkis Clinical Trials

    Gainesville, Florida, 32607

  • Sun Valley Research Center

    Imperial, California, 92251

  • Lake Charles Clinical Trials

    Lake Charles, Louisiana, 70629

  • Synergy Clinical Research Center

    Lemon Grove, California, 91945

  • Woodland International Research Group

    Little Rock, Arkansas, 72211

  • Alliance for Wellness dba Alliance for Research

    Long Beach, California, 90807

  • Northwest Behavioral Research Center

    Marietta, Georgia, 30060

  • Research Strategies Of Memphis, Llc

    Memphis, Tennessee, 38119

  • North Star Medical Research, LLC

    Middleburg Heights, Ohio, 44130

  • AMR- Baber Research, Inc.

    Naperville, Illinois, 60563

  • Manhattan Behavioral Medicine

    New York, New York, 10036

  • IPS Research Company

    Oklahoma City, Oklahoma, 73106

  • Paradigm Research Professionals, LLC

    Oklahoma City, Oklahoma, 73118

  • NRC Research Institute

    Orange, California, 92868

  • Medical Research Group of Central Florida

    Orange City, Florida, 32763

  • Aspen Clinical Research, LLC

    Orem, Utah, 84058

  • Asclepes Research Center

    Panorama City, California, 91402

  • AIM Trials, LLC

    Plano, Texas, 75093

  • Research Across America

    Plano, Texas, 75093

  • Princeton Medical Institute

    Princeton, New Jersey, 08540

  • Finger Lakes Clinical Research

    Rochester, New York, 14618

  • St. Charles Psychiatric Associates - Midwest Research Group

    Saint Charles, Missouri, 63304

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas, 78229

  • Millennium Psychiatric Associates, LLC

    St Louis, Missouri, 63132

  • AMR Conventions Research

    Warrenville, Illinois, 60555

  • Children's National Medical Center Merge

    Washington D.C., District of Columbia, 20010

  • Kansas University School of Medicine-Wichita

    Wichita, Kansas, 67214

Other trials in United States

Russia13 sites
  • Arkhangelsk Regional Clinical Mental Hospital

    Arkhangelsk, 163530

  • GUZ Engels Psychiatric Hospital

    Engel's, 413124

  • State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ...

    Krasnodar, 350007

  • LLC City Neurological Center Sibneuromed

    Novosibirsk, 630091

  • Medicorehabilitation Research Center Phoenix

    Rostov-on-Don, Rostov State, 344010

  • Rostov State Medical University of the Minzdravsotsrazvitiya of Russia

    Rostov-on-Don, 344022

  • City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov

    Saint Petersburg, 197341

  • Saratov State Medical University

    Saratov, 410028

  • Guz Saratov Regional Psychiatric Hospital St. Sofii

    Saratov, 410060

  • Stavropol Region Psychiatric Hospital No.2

    Stavropol, Stavropol Kray, 357034

  • Nebbiolo LLC

    Tomsk, 634009

  • Yaroslavl Regional Clinical Psychiatry Hospital

    Yaroslavl, 150003

  • State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi...

    Yekaterinburg, 620030

Other trials in Russia

Mexico9 sites
  • ICARO Investigaciones en Medicina S.A. de C.V.

    Chihuahua City, 31000

  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C

    Culiacan de Rosales, Sinaloa, 80230

  • Centro Investigacion Medico Biologica Y Terapia Avanzada

    Guadalajara, Jalisco, 44130

  • Clinica Cemelli

    Guadalajara, Jalisco, 44200

  • Roberto Zepeda Sanchez

    Guadalajara, Jalisco, 44690

  • B & B Investigaciones Medicas, SC

    Mazatlán, Sinaloa, 82140

  • Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)

    Mexico City, Mexico City, 04530

  • CRI Centro Regiomontano de Investigacion SC

    Monterrey, Nuevo León, 64060

  • BIND Investigaciones S.C

    San Luis Potosí City, 78213

Other trials in Mexico

Poland6 sites
  • Prywatne Gabinety Lekarskie Promedicus

    Bialystok, Podlaskie Voivodeship, 15879

  • Centrum Badan Klinicznych PI-House Sp. z o.o.

    Gdansk, 80-546

  • Przychodnia Syntonia Poradnia Zdrowia Psychicznego

    Kielce, 25-103

  • Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny

    Lublin, 20-884

  • Filip Rybakowski Specjalistyczna Praktyka Lekarska

    Poznan, 60-744

  • Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu

    Wałbrzych, 58300

Other trials in Poland

Serbia5 sites
  • Child and Adolescent Neurology and Psychiatry Clinic

    Belgrade, 11000

  • Institute of Mental Health

    Belgrade, 11000

  • University Clinical Center Kragujevac

    Kragujevac, 34000

  • Clinical Center of Vojvodina - Clinic of Psychiatry

    Novi Sad, 21000

  • Daily Hospital for Children and Adolescents

    Pantelej-Nis, 18000

Other trials in Serbia

Colombia4 sites
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS.

    Barranquilla, Atlántico, 80020

  • E.S.E. Hospital Mental de Antioquia HOMO

    Bello, Antioquia, 51050

  • Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS

    Bogotá, DC, 111166

  • Psynapsis Salud Mental S.A.

    Pereira, Risaralda Department

Other trials in Colombia

Ukraine4 sites
  • Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro...

    Kyiv, 04080

  • Odessa Regional Medical Centre of Mental Health

    Odesa, 65006

  • Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U...

    Poltava, 36013

  • Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers...

    Ternopil, 46000

Other trials in Ukraine

France3 sites
  • Cabinet Psyche

    Douai, Nord, 59500

  • Centre Medical Ambroise Pare

    Élancourt, 78990

  • CHU de Nantes - Hopital Hotel Dieu

    Nantes, 44093

Other trials in France

Israel3 sites
  • Shalvata Mental Health Center

    Hod HaSharon, 4534708

  • Ramat Chen - Mental Health Clinic

    Tel Aviv, 6435807

  • The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital

    Tel HaShomer, 5262000

Other trials in Israel

Italy3 sites
  • Scientific Institute Fondazione Stella Maris

    Calambrone Pisa, Pisa, 56026

  • University Federico II Of Naples

    Naples, 80131

  • Sciaf Ulss 16 Padova

    Padova, Regione Veneto, 35143

Other trials in Italy

Bulgaria2 sites
  • MHAT Targovishte AD

    Targovisthe, 7700

  • Diagnostic Consultative Center Mladost-M Varna OOD

    Varna, 9020

Other trials in Bulgaria

Hungary2 sites
  • Vadaskert Alapitvany

    Budapest, 1021

  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza

    Gyula, 5700

Other trials in Hungary

Latvia2 sites
  • Linda Keruze's Psychiatric Center, LLC

    Liepāja, LV-3401

  • Children Hospilal -Gailezers

    Riga, 1079

Other trials in Latvia

South Africa2 sites
  • Cape Trial Centre

    Bellville, Cape Town, 7530

  • Tara Hospital

    Sandhurst, Gauteng, 2196

Other trials in South Africa

Spain2 sites
  • Hospital Universitario Fundacion Alcorcon

    Alcorcón, Madrid, 28922

  • Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo

    Torremolinos, Malaga, 29620

Other trials in Spain

Canada1 site
  • Paediatric Sleep Research Inc.

    Toronto, Ontario, M5S 3A3

Other trials in Canada

Estonia1 site
  • Marienthali Kliinik

    Tallinn, 11315

Other trials in Estonia

Germany1 site
  • Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri

    Mainz, 55122

Other trials in Germany

South Korea1 site
  • Seoul National University Hospital

    Seoul, 03080

Other trials in South Korea

About this study

Official title: Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).

Being tested
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Keywords
paediatric
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vortioxetine 10 mg/dayDrug

    Also called Brintellix ®, Lu AA21004

    10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

    Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

  • Vortioxetine 20 mg/dayDrug

    Also called Brintellix ®, Lu AA21004

    20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

    Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

  • Fluoxetine 20mg/dayDrug

    20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).

    Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

  • PlaceboOther

    Encapsulated tablet, orally

Study groups in NCT02709655
Study groupRoleWhat they receive
Vortioxetine 10 mg/dayExperimentalNot described
Receives: Drug: Vortioxetine 10 mg/day
Vortioxetine 20 mg/dayExperimentalNot described
Receives: Drug: Vortioxetine 20 mg/day
Fluoxetine 20 mg/day,Active comparatorA decision has been taken to stop recruitment into this treatment arm.
Receives: Drug: Fluoxetine 20mg/day
PlaceboPlacebo comparatorNot described
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.

    Measured: Baseline (Week 4 of Phase A), Week 8 of Phase B

Secondary outcomes (20)
  1. Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B

  2. Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B

    The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.

    Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

  3. Percentage of Participants With CDRS-R Response

    CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline [Randomization])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Measured: Weeks 2, 4, 6, and 8 of Phase B

  4. Percentage of Participants With CDRS-R Remission

    CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Measured: Weeks 2, 4, 6, and 8 of Phase B

  5. Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B

    The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.

    Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

  6. Parent Global Assessment (PGA) Score

    The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Measured: Weeks 2, 4, 6, and 8 of Phase B

  7. Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B

    The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

    Measured: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  8. Clinical Global Impression - Global Improvement (CGI-I) Score

    The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Measured: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  9. Percentage of Participants With CGI-S Remission

    CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

    Measured: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  10. Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B

    The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  11. Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  12. Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  13. Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  14. Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  15. Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  16. Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  17. Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  18. Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  19. Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B

    The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  20. Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B

    The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

    Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2016 (estimated)
  2. Study start18 May 2016
  3. Primary completion21 Jan 2022
  4. Study completion21 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
683 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02709655
Sponsor's protocol ID
12709A
Other IDs
2008-005353-38, 2008
Status last verified
Aug 2022
First submitted
11 Mar 2016
Last updated
22 Sep 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Huss M, Findling RL, DelBello MP, Necking O, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study. JAACAP Open. 2024 Nov 22;3(3):736-748. doi: 10.1016/j.jaacop.2024.11.002. eCollection 2025 Sep.

    PubMed 40922774

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 98 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 98 sites in United States, Russia, Mexico, Poland, Serbia and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (time frame: Baseline (Week 4 of Phase A), Week 8 of Phase B). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02709655, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in